|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current guidelines for the management of non-alcoholic fatty liver disease:A systematic review with comparative analysis显示文摘The current epidemic of non-alcoholic fatty liver disease(NAFLD) is reshaping the field of hepatology all around the world.The widespread diffusion of metabolic risk factors such as obesity,type2-diabetes mellitus,and dyslipidemia has led to a worldwide diffusion of NAFLD.In parallel to the increased availability of effective anti-viral agents,NAFLD is rapidly becoming the most common cause of chronic liver disease in Western Countries,and a similar trend is expected in Eastern Countries in the next years.This epidemic and its consequences have prompted experts from all over the word in identifying effective strategies for the diagnosis,management,and treatment of NAFLD.Different scientific societies from Europe,America,and Asia-Pacific regions have proposed guidelines based on the most recent evidence about NAFLD.These guidelines are consistent with the key elements in the management of NAFLD,but still,show significant difference about some critical points.We reviewed the current literature in English language to identify the most recent scientific guidelines about NAFLD with the aim to find and critically analyse the main differences.We distinguished guidelines from 5 different scientific societies whose reputation is worldwide recognised and who are representative of the clinical practice in different geographical regions.Differences were noted in: the definition of NAFLD,the opportunity of NAFLD screening in high-risk patients,the noninvasive test proposed for the diagnosis of NAFLD and the identification of NAFLD patients with advanced fibrosis,in the follow-up protocols and,finally,in the treatment strategy(especially in the proposed pharmacological management).These difference have been discussed in the light of the possible evolution of the scenario ofNAFLD in the next years. | Simona Leoni Francesco Tovoli Lucia Napoli Ilaria Serio Silvia Ferri Luigi Bolondi | 2018 | World Journal of Gastroenterology2018，24，30： | 42 |
| 2 | Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma显示文摘Epithelioid hemangioendothelioma(EH)is a rare tumor arising from the vascular endothelial cells of soft tissue or visceral organs.The most common visceral site is the liver,where it is often involved in a multifocal man-ner known as hepatic EH(HEH).Surgical resection with curative intent represents the gold standard therapy.When surgery is not feasible,or in cases of metastatic disease,no standard medical treatment is currently indicated.In small series,drugs with anti-angiogenic activity(such as bevacizumab,sorafenib,thalidomide,and lenalidomide)have been proposed with promising results.We describe a 73-year-old man with multifocal non-resectable HEH treated with lenalidomide.Disease status was evaluated by abdominal ultrasound and magnetic resonance every four months.The patient was treated for a total of 39 mo with prolonged disease stabilization and,at the time of writing,is still under treatment with a good tolerance profile.During a short period of treatment discontinuation,the disease showed slight progression that immediately resolved after the reintroduction of lenalidomide.Lenalidomide may represent a valid treatment option for HEH due to its anti-angiogenic and antineoplastic activities.This preliminary result merits further study in a large series. | Maria Caterina Pallotti Margherita Nannini Claudio Agostinelli Simona Leoni Valerio Di Scioscio Anna Mandrioli Cristian Lolli Maristella Saponara Stefano Pileri Luigi Bolondi Guido Biasco Maria Abbondanza Pantaleo | 2014 | World Journal of Gastroenterology2014，20，22： | 9 |
| 3 | Negative Feedback Regulation of Auxin Signaling by ATHB8/ACL5-BUD2 Transcription Module显示文摘 | Simona Baima Valentina Forte Marco Possenti Andres Penalosa Guido Leoni Sergio Salvi Barbara Felici Ida Ruberti Giorgio Morelli | 2014 | Molecular Plant2014，7，6： | 4 |
| 4 | Viral hepatitis:Innovations and expectations显示文摘Viral hepatitis is a significant health problem worldwide,associated with morbidity and mortality.Hepatitis B,C,D,and occasionally E viruses(HBV,HCV,HDV,and HEV)can evolve in chronic infections,whereas hepatitis A virus(HAV)frequently produces acute self-limiting hepatitis.In the last years,different studies have been performed to introduce new antiviral therapies.The most important goal in the treatment of viral hepatitis is to avoid chronic liver disease and complications.This review analyzes currently available therapies,in particular for viruses associated with chronic liver disease.The focus is especially on HBV and HCV therapies,investigating new drugs already introduced in clinical practice and clinical trials.We also describe new entry inhibitors,developed for the treatment of chronic HDV and HBV and currently available treatments for HEV.The last drugs introduced have shown important efficacy in HCV,with achievable target HCV elimination by 2030.Concurrently,renewed interest in curative HBV therapies has been registered;current nucleotide/nucleoside analogs positively impact liver-related complications,ensuring high safety and tolerability.Novel approaches to HBV cure are based on new antivirals,targeting different steps of the HBV life cycle and immune modulators.The improved knowledge of the HDV life cycle has facilitated the development of some direct-acting agents,as bulevirtide,the first drug conditionally approved in Europe for HDV associated compensated liver disease.Further studies are required to identify a new therapeutic approach in hepatitis E,especially in immunosuppressed patients. | Simona Leoni Alberto Casabianca Benedetta Biagioni Ilaria Serio | 2022 | World Journal of Gastroenterology2022，28，5： | 3 |
| 5 | Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: Experience of the Bologna Liver Oncology Group显示文摘 | Simona Leoni Fabio Piscaglia Ilaria Serio Eleonora Terzi Irene Pettinari Luca Croci Sara Marinelli Francesca Benevento Rita Golfieri Luigi Bolondi | 2014 | Digestive and Liver Disease2014，，： | 2 |
| 6 | Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound显示文摘 | Marzia Galassi Massimo Iavarone Sandro Rossi Simona Bota Sara Vavassori Laura Rosa Simona Leoni Laura Venerandi Sara Marinelli Angelo Sangiovanni Letizia Veronese Mirella Fraquelli Alessandro Granito Rita Golfieri Massimo Colombo Luigi Bolondi Fabio Pisca | 2013 | Liver Int2013，，5： | 1 |
| 7 | Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound显示文摘 | Marzia Galassi Massimo Iavarone Sandro Rossi Simona Bota Sara Vavassori Laura Rosa Simona Leoni Laura Venerandi Sara Marinelli Angelo Sangiovanni Letizia Veronese Mirella Fraquelli Alessandro Granito Rita Golfieri Massimo Colombo Luigi Bolondi Fabio Pisca | 2013 | Liver Int2013，，5： | 1 |
| 8 | Characterization of liver lesions by real-time contrast-enhanced ultrasonography显示文摘 | Natascia Celli Stefano Gaiani Fabio Piscaglia Gianni Zironi Valeria Camaggi Simona Leoni Roberto Righini Luigi Bolondi | 2007 | European Journal of Gastroenterology & Hepatology2007，，1： | 1 |
| 9 | The role of ultrasound elastographic techniques in chronic liver disease: Current status and future perspectives显示文摘 | Fabio Piscaglia Sara Marinelli Simona Bota Carla Serra Laura Venerandi Simona Leoni Veronica Salvatore | 2013 | European Journal of Radiology2013，，： | 1 |
| 10 | The role of ultrasound elastographic techniques in chronic liver disease: Current status and future perspectives显示文摘 | Fabio Piscaglia Sara Marinelli Simona Bota Carla Serra Laura Venerandi Simona Leoni Veronica Salvatore | 2014 | European Journal of Radiology2014，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员